Natera increased its 2026 guidance after first-quarter 2026 revenue jumped 39% year over year, reflecting strength across its clinical oncology business and women’s health testing. Management said Q1 also marked the first time it delivered one million units in a single quarter. For 2026, Natera now guides for revenue of $2.74 billion to $2.82 billion, up from prior guidance of $2.62 billion to $2.70 billion at the midpoint. The company attributed gains to higher unit volumes in women’s health, continued adoption of its expanded Fetal Focus test, and growth in oncology test processing. In minimal residual disease testing, Natera said it is on track for a 1 million-tests annual run rate, and highlighted trial data support and commercial footprint expansion alongside Flatiron Health OncoEMR integration. The company also raised its average selling price for Signatera from $1,225 to $1,250.